Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8056 to 8070 of 9023 results

  1. Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]

    In development Reference number: GID-TA11848 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. ALXN1840 for treating Wilson disease [ID6422]

    In development Reference number: GID-TA11449 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Acute bowel obstruction

    Discontinued Reference number: GID-NG10377

    NICE guideline
    Discontinued

  4. Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]

    Discontinued Reference number: GID-TA11262

    Technology appraisal guidance
    Discontinued

  5. Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

    Discontinued Reference number: GID-TA10502

    Technology appraisal guidance
    Discontinued

  6. Inpatient mental health settings

    Discontinued Reference number: GID-SGWAVE0701

    Safe staffing guideline
    Discontinued

  7. Accident and emergency departments

    Discontinued Reference number: GID-SGWAVE0762

    Safe staffing guideline
    Discontinued

  8. Mental health community settings

    Discontinued Reference number: GID-SGWAVE0702

    Safe staffing guideline
    Discontinued

  9. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued Reference number: GID-TA11151

    Technology appraisal guidance
    Discontinued

  10. Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]

    Discontinued Reference number: GID-TA11647

    Technology appraisal guidance
    Discontinued

  11. Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [ID6678]

    In development Reference number: GID-TA11805 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Discontinued Reference number: GID-TA11399

    Technology appraisal guidance
    Discontinued

  13. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued Reference number: GID-TA11259

    Technology appraisal guidance
    Discontinued

  14. Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]

    Discontinued Reference number: GID-TA11257

    Technology appraisal guidance
    Discontinued

  15. Capecitabine for the treatment of advanced pancreatic cancer [ID127]

    Discontinued Reference number: GID-TA11239

    Technology appraisal guidance
    Discontinued